Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

All-Trans Retinoic Acid Enhances the Cytotoxic Effect of T Cells with Anti-CD38 Chimeric Receptor in Acute Myeloid Leukemia

Keichiro Mihara, MD, PhD, Joyeeta Bhattacharyya, MD, PhD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD

Blood (2012) 120 (21): 1901.

https://doi.org/10.1182/blood.V120.21.1901.1901

Published: 2012

Journal Articles

T-Cell Immunotherapy with a Chimeric Receptor Against CD38 Is Effective in Eliminating Myeloma Cells

Keichiro Mihara, MD, PhD, Joyeeta Bhattacharyya, MD, PhD, Akira Kitanaka, MD, PhD, Akihiro Ihara, MD, PhD, Akira Sakai, MD, PhD, Yoshiaki Kuroda, MD, PhD, Hideki Asaoku, MD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD

Blood (2011) 118 (21): 885.

https://doi.org/10.1182/blood.V118.21.885.885

Published: 2011

Journal Articles

Expansion of CD8 + /perforin + T-Cell Subset in Patients Predicts Response to Cyclosporin A Therapy in Patients with Erythroid Hypoplasia/Aplasia

Hideaki Nitta, MD, Yuka Harada, MD, Hideo Hyodo, MD, Akiro Kimura, MD, Hironori Harada, MD

Blood (2011) 118 (21): 1337.

https://doi.org/10.1182/blood.V118.21.1337.1337

Published: 2011

Journal Articles

BMI1 Collaborates with RUNX1/AML1 Mutants in the Development of Human Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML)

Hironori Harada, MD, Ye Ding, MD, Jun Imagawa, MD, Takahiko Miyama, MD, Akiro Kimura, MD, Yuka Harada, MD

Blood (2011) 118 (21): 275.

https://doi.org/10.1182/blood.V118.21.275.275

Published: 2011

Journal Articles

Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia

Jun Imagawa, Yuka Harada, Takeshi Shimomura, Hideo Tanaka, Yoshiko Okikawa, Hideo Hyodo, Akiro Kimura, Hironori Harada

Blood (2010) 116 (26): 6018–6022.

https://doi.org/10.1182/blood-2010-06-289389

Published: 2010

Journal Articles

B-Cell Lymphoma Cells Overexpressing BMI-1 Are Correlated with Drug Resistance through Enhanced Expression of Survivin and Are Effectively Eliminated by T Cells with Anti-CD38 Chimeric Receptor

Joyeeta Bhattacharyya, Keichiro Mihara, MD, PhD, Motoaki Ohtsubo, Shin'ichiro Yasunaga, MD, PhD, Yoshihiro Takihara, MD, PhD, Masaharu Hoshi, Akiro Kimura, MD, PhD

Blood (2010) 116 (21): 3613.

https://doi.org/10.1182/blood.V116.21.3613.3613

Published: 2010

Journal Articles

Establishment of An HS23 Stromal Cell-Dependent Myeloma Cell Line: Fibronectin and IL-6 Are Critical for Survival

Akira Sakai, MD, PhD, Miyo Oda, PhD, Noriaki Yoshida, MD, Mitsuhiro Itagaki, MD, Koji Arihiro, MD, PhD, Akiro Kimura, MD, PhD

Blood (2010) 116 (21): 2949.

https://doi.org/10.1182/blood.V116.21.2949.2949

Published: 2010

Journal Articles

AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms

Ye Ding, Yuka Harada, Jun Imagawa, Akiro Kimura, Hironori Harada

Blood (2009) 114 (25): 5201–5205.

https://doi.org/10.1182/blood-2009-06-223982

Published: 2009

Journal Articles

Six Month Treatment of Low Dose Eltrombopag Is Efficacious in Japanese Patients with Refractory Chronic Immune Thrombocytopenic Purpura (ITP).

Yoshiaki Tomiyama, MD, Yoshitaka Miyakawa, MD, PhD, Shinichiro Okamoto, MD, PhD, Shinya Katsutani, MD, Akiro Kimura, MD, Yasushi Okoshi, MD, PhD, Haruhiko Ninomiya, MD, PhD, Hiroshi Kosugi, MD, PhD, Shosaku Nomura, MD, Katsutoshi Ozaki, MD, Yasuo Ikeda, MD, Nobuyuki Koh, Koichi Katsura, MD, PhD, Yuzuru Kanakura, MD, PhD

Blood (2009) 114 (22): 1324.

https://doi.org/10.1182/blood.V114.22.1324.1324

Published: 2009

Journal Articles

AML1/RUNX1 Point Mutation Possibly Promotes Leukemic Transformation in Myeloproliferative Disorders.

Jun Imagawa, MD, Yuka Harada, MD, Ye Ding, MD, Akiro Kimura, MD, PhD, Hironori Harada, MD, PhD

Blood (2009) 114 (22): 1902.

https://doi.org/10.1182/blood.V114.22.1902.1902

Published: 2009

Journal Articles

Levels of sIL-2R in Sera Depend On Number of CD25-Positive Lymphoma Cells and MMP-9-Positive Macrophages in DLBCL.

Noriaki Yoshida, MD, Akira Sakai, MD, PhD, Yoshiko Okikawa, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, MD, Hirotaka Matsui, MD, PhD, Koji Arihiro, MD, PhD, Megumu Fujihara, MD, PhD, Takashi Nishisaka, MD, PhD, Naomi Sasaki, MD, PhD, Yoshito Sadahira, MD, PhD, Akiro Kimura, MD, PhD

Blood (2009) 114 (22): 2927.

https://doi.org/10.1182/blood.V114.22.2927.2927

Published: 2009

Journal Articles

Acquired Pure Red Cell Aplasia Associated with Malignant Lymphomas: A Nationwide Cohort Study in Japan

Makoto Hirokawa, Ken-ichi Sawada, Naohito Fujishima, Fumio Kawano, Akiro Kimura, Takashi Watanabe, Ayako Arai, Toshimitsu Matsui, Shinji Nakao, Akio Urabe, Mitsuhiro Omine, Keiya Ozawa

Blood (2008) 112 (11): 4112.

https://doi.org/10.1182/blood.V112.11.4112.4112

Published: 2008

Journal Articles

Synergistic and Persistent Effect of T-Cell Immunotherapy with Anti-CD19 or Anti-CD38 Chimeric Receptor on B-Cell Lymphoma in Conjunction with Rituximab

Keichiro Mihara, MD, PhD, Kazuyoshi Yanagihara, PhD, Misato Takigahira, PhD, Yoshihiro Takihara, MD, PhD, Akiro Kimura, MD, PhD

Blood (2008) 112 (11): 2610.

https://doi.org/10.1182/blood.V112.11.2610.2610

Published: 2008

Journal Articles

Significance of Serum Soluble IL-2R in DLBCL and FL Is Different from That in ATL

Noriaki Yoshida, MD, Akira Sakai, MD, PhD, Yoshiko Okikawa, MD, Hideaki Nitta, MD, Takashi Nishisaka, MD, PhD, Akiro Kimura, MD, PhD

Blood (2008) 112 (11): 2817.

https://doi.org/10.1182/blood.V112.11.2817.2817

Published: 2008

Journal Articles

Cyclin D1 Overexpression Increases Chemosensitivity Via Prolonged S-Phase and TRAIL Signal in Myeloma Cell.

Yoshiaki Kuroda, MD, Akira Sakai, M.D., Naohiro Tsuyama, Ph.D., Yuta Katayama, M.D., Shoso Munemasa, M.D., Yoshiko Okikawa, M.D., Hideki Asaoku, M.D., Nanae Nakaju, Mami Mizuno, Takashi Nishizaka, M.D., Katsunari Ogawa, Hideo Tanaka, M.D., Akiro Kimura, M.D.

Blood (2007) 110 (11): 3530.

https://doi.org/10.1182/blood.V110.11.3530.3530

Published: 2007

Journal Articles

Activated T Cell-Mediated Immunotherapy with a Chimeric Receptor Against CD38 in B-Cell Malignancies.

Keichiro Mihara, MD, PhD, Kazuyoshi Yanagihara, Ph.D, Misato Takigahira, Takahiro Ochiya, Ph.D, Chihaya Imai, M.D., Ph.D, Akira Kitanaka, M.D., Ph.D, Yoshihiro Takihara, M.D., Ph.D, Akiro Kimura, M.D., Ph.D

Blood (2007) 110 (11): 2356.

https://doi.org/10.1182/blood.V110.11.2356.2356

Published: 2007

Journal Articles

Immunomodulatory Thalidomide Analogs Do Not Affect Osteoprogenitor Differentiation and Low Concentration of Bortezomib Promotes It, While Both Agents Suppress Osteoclast Differentiation.

Shoso Munemasa, MD, Akira Sakai, M.D., Yoshiaki Kuroda, M.D., Yoshiko Okikawa, M.D., Yuta Katayama, M.D., Hideki Asaoku, M.D., Tadahiko Kubo, M.D., Shoji Shimose, M.D., Akiro Kimura, M.D.

Blood (2007) 110 (11): 4780.

https://doi.org/10.1182/blood.V110.11.4780.4780

Published: 2007

Journal Articles

Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan

Masanao Teramura, Akiro Kimura, Satsuki Iwase, Yuji Yonemura, Shinji Nakao, Akio Urabe, Mitsuhiro Omine, Hideaki Mizoguchi

Blood (2007) 110 (6): 1756–1761.

https://doi.org/10.1182/blood-2006-11-050526

Published: 2007

Includes: Supplemental data

Journal Articles

Cyclin D1 Overexpression Increases Chemosensitivity Via the Induction of Bim in Myeloma Cells.

Yoshiaki Kuroda, MD, Akira Sakai, M.D., Naohiro Tsuyama, Ph.D., Shoso Munemasa, M.D., Nanae Nakaju, Mami Mizuno, Yoshiko Okikawa, M.D., Yuta Katayama, M.D., Akiro Kimura, M.D.

Blood (2006) 108 (11): 3418.

https://doi.org/10.1182/blood.V108.11.3418.3418

Published: 2006

Journal Articles

Connective Tissue Growth Factor (CTGF) Is an Indicator of Bone Involvement in Multiple Myeloma.

Shoso Munemasa, MD, Akira Sakai, M.D., Yoshiaki Kuroda, M.D., Yoshiko Okikawa, M.D., Yuta Katayama, M.D., Hideki Asaoku, M.D., Tadahiko Kubo, M.D., Noelynn Oliver, Ph.D., Akiro Kimura, M.D.

Blood (2006) 108 (11): 5025.

https://doi.org/10.1182/blood.V108.11.5025.5025

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

All-Trans Retinoic Acid Enhances the Cytotoxic Effect of T Cells with Anti-CD38 Chimeric Receptor in Acute Myeloid Leukemia

T-Cell Immunotherapy with a Chimeric Receptor Against CD38 Is Effective in Eliminating Myeloma Cells

Expansion of CD8 + /perforin + T-Cell Subset in Patients Predicts Response to Cyclosporin A Therapy in Patients with Erythroid Hypoplasia/Aplasia

BMI1 Collaborates with RUNX1/AML1 Mutants in the Development of Human Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML)

Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia

B-Cell Lymphoma Cells Overexpressing BMI-1 Are Correlated with Drug Resistance through Enhanced Expression of Survivin and Are Effectively Eliminated by T Cells with Anti-CD38 Chimeric Receptor

Establishment of An HS23 Stromal Cell-Dependent Myeloma Cell Line: Fibronectin and IL-6 Are Critical for Survival

AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms

Six Month Treatment of Low Dose Eltrombopag Is Efficacious in Japanese Patients with Refractory Chronic Immune Thrombocytopenic Purpura (ITP).

AML1/RUNX1 Point Mutation Possibly Promotes Leukemic Transformation in Myeloproliferative Disorders.

Levels of sIL-2R in Sera Depend On Number of CD25-Positive Lymphoma Cells and MMP-9-Positive Macrophages in DLBCL.

Acquired Pure Red Cell Aplasia Associated with Malignant Lymphomas: A Nationwide Cohort Study in Japan

Synergistic and Persistent Effect of T-Cell Immunotherapy with Anti-CD19 or Anti-CD38 Chimeric Receptor on B-Cell Lymphoma in Conjunction with Rituximab

Significance of Serum Soluble IL-2R in DLBCL and FL Is Different from That in ATL

Cyclin D1 Overexpression Increases Chemosensitivity Via Prolonged S-Phase and TRAIL Signal in Myeloma Cell.

Activated T Cell-Mediated Immunotherapy with a Chimeric Receptor Against CD38 in B-Cell Malignancies.

Immunomodulatory Thalidomide Analogs Do Not Affect Osteoprogenitor Differentiation and Low Concentration of Bortezomib Promotes It, While Both Agents Suppress Osteoclast Differentiation.

Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan

Cyclin D1 Overexpression Increases Chemosensitivity Via the Induction of Bim in Myeloma Cells.

Connective Tissue Growth Factor (CTGF) Is an Indicator of Bone Involvement in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only